Trial Services
ATIC provides a range of trial services to support both commercial and investigator-initiated projects.
Community Resources
Co-designed with our Community Engagement Panel, ATIC offers resources for both the healthcare professionals and the community.
Health Professionals
Access to ATIC’s Beyond Insulin Seminar series, clinical recommendations and guidelines, and support for your next project.
What does ATIC do?
ATIC is working across six distinct interconnected Domains to ensure maximum impact and fulfil our bold vision.
Clinical trials
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Community engagement
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Data management
Harmonise data collection and ensure linkage with national and international diabetes networks.
Education and training
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Preclinical and translation
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
Regulation and government
Advocate for regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
MT-101-101 Trial - Promising Interim Results
Early results from a small clinical trial conducted in Australia show that MTX‑101, a new immune‑targeting therapy, may help protect the insulin‑producing cells in people with type 1 diabetes. While more data is required, participants receiving higher doses showed signs of positive immune responses and maintained or improved insulin production, offering hope that the treatment may slow progression of type 1 diabetes.
Further results from the BANDIT Study
August 2026
Further results from the BANDIT study have been published in Diabetes Care.
ATIC at IDF-WPR, ADC & Metabolic diseases 2026
August 2026
Heading to the 2026 combined IDF-WPR, ADC & Metabolic diseases congress? ATIC is too! Check out our list of must-see presentations.
Novel approaches to metabolic control in diabetes: Multianalyte Sensing and Gene Therapy
June 2026
Seminar 32, Beyond Insulin Seminar Series – Professor David O’Neal presents novel approaches to metabolic control in diabetes.
Tzield (Teplizumab) Set to Transform Type 1 Diabetes Care in Australia
May 2026
The approval of Tzield® (teplizumab) by the Therapeutic Goods Administration (TGA) marks the first therapy available to delay the onset of clinical type 1 diabetes.
Working with leaders in our field
Supported by
Administered by
Collaborators
